Drug intelligence / Profile preview

lamivudine + adefovir + entecavir + HBIG

Development stage: Preclinical
Lead developer: GSK
Modality: Small Molecules
Administration: Oral, Intramuscular, Intravenous

Overview

A combination therapy consisting of three nucleoside/nucleotide analogue reverse transcriptase inhibitors (lamivudine, adefovir, and entecavir) plus Hepatitis B Immune Globulin (HBIG). This combination is likely used for the treatment of chronic hepatitis B virus (HBV) infection, particularly in cases with resistance to individual antiviral medications or in post-liver transplant settings to prevent HBV recurrence.

Targets

HBV Pol (Hepatitis B virus polymerase)HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on lamivudine + adefovir + entecavir + HBIG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lamivudine + adefovir + entecavir + HBIG.

Explore the full profile